.png){kind=icon}
.png){kind=icon}
Return
Medications for obesity
.png){kind=icon}
PRE
AI
DOI：10.1016/j.actpha.2026.03.006.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Research into the causes of obesity has highlighted the major role played by the leptin-melanocortin pathway. Alongside orlistat, a gastrointestinal lipase inhibitor, two new classes of drugs have emerged: agonists of the glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide receptors, and melanocortin-4 receptor agonists. Regardless of the medication used, dietary measures combined with therapeutic and nutritional education remain essential for long-term control of weight gain.
Keywords:
liraglutide
obesity
orlistat
semaglutide
setmelanotide
tirzepatide
Journal
A
IF:
0.1
Papers:
155
Citations:
0